A Phase II Study of Intravenous DX-8951f [exatecan] Administered Daily for Five Days Every Three Weeks to Patients With Advanced or Recurrent Squamous Cell Cancer of the Cervix

Trial Profile

A Phase II Study of Intravenous DX-8951f [exatecan] Administered Daily for Five Days Every Three Weeks to Patients With Advanced or Recurrent Squamous Cell Cancer of the Cervix

Completed
Phase of Trial: Phase II

Latest Information Update: 14 Aug 2017

At a glance

  • Drugs Exatecan (Primary)
  • Indications Cervical cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 25 Oct 2007 Status changed from suspended to completed.
    • 11 Sep 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top